title: P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells.
abstract: BACKGROUND
  Our previous study demonstrated that extracellular adenosine 5'-triphosphate (ATP) stimulated prostate cancer cell invasion via P2Y receptors. However, the purinergic receptor subtype(s) involved in this process remains unclear. Here we aimed to determine whether P2Y2, one subtype of P2Y receptors, was involved in the invasion and metastasis of prostate cancer cells, and elucidated the underlying mechanism.
  
  
  METHODS
  RNAi was introduced to silence the expression of P2Y2. In vitro invasion and migration assays and in vivo experiments were carried out to examine the role of P2Y2 receptor in cell invasion and metastasis. cDNA microarray was performed to identify the differentially expressed genes downstream of ATP treatment.
  
  
  RESULTS
  P2Y2 was significantly expressed in the prostate cancer cells. Knockdown of P2Y2 receptor suppressed cell invasion and metastasis in vitro and in vivo. Further experiments identified that ATP could promote IL-8 and Snail expression and inhibit E-cadherin and Claudin-1 expression. Knockdown of P2Y2 receptor affected the expression of these EMT/invasion-related genes in vitro and in vivo.
  
  
  CONCLUSIONS
  P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells via some EMT/invasion-related genes. Thereby, P2Y2 receptor could be a potential therapeutic target for the treatment of prostate cancer.
authors: 1] Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Health Science Center, Beijing 100191, China [2] Department of Pathology, Peking University Health Science Center, Beijing 100191, China.
authors: W-H
authors: WH
authors: Li
authors: Y
authors: Y
authors: Qiu
authors: H-Q
authors: HQ
authors: Zhang
authors: Y
authors: Y
authors: Liu
authors: J-F
authors: JF
authors: You
authors: X-X
authors: XX
authors: Tian
authors: W-G
authors: WG
authors: Fang
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D034622:RNA Interference; D058473:Receptors, Purinergic P2Y2 / Q000235:genetics / Q000378:metabolism*; D014162:Transfection
chemical_list: D058473:Receptors, Purinergic P2Y2
references: Cancer Res. 2012 Nov 1;72(21):5441-7
references: 23090120
references: Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L376-85
references: 12691958
references: J Biol Chem. 1998 Sep 4;273(36):23110-7
references: 9722539
references: PLoS One. 2012;7(5):e36923
references: 22666335
references: Cancer Metastasis Rev. 2001;20(3-4):279-86
references: 12085966
references: Int J Cancer. 2003 Oct 20;107(1):1-10
references: 12925950
references: Br J Pharmacol. 2003 Apr;138(7):1244-50
references: 12711624
references: Br J Cancer. 2010 Feb 16;102(4):639-44
references: 20087353
references: Science. 2006 Dec 15;314(5806):1792-5
references: 17170310
references: Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G223-30
references: 16920697
references: Nat Med. 2006 Aug;12(8):895-904
references: 16892035
references: Int J Colorectal Dis. 2001 Jun;16(3):154-66
references: 11459289
references: Oncogene. 2014 May 1;33(18):2307-16
references: 23686305
references: Cancer Lett. 2005 Jun 16;224(1):81-91
references: 15911103
references: Cancer Lett. 2004 Nov 25;215(2):239-47
references: 15488643
references: Biochim Biophys Acta. 2011 Aug;1816(1):73-9
references: 21515339
references: PLoS One. 2008 Jul 09;3(7):e2599
references: 18612415
references: Oncogene. 2010 Sep 30;29(39):5346-58
references: 20661219
references: J Biol Chem. 2005 Nov 25;280(47):39050-7
references: 16186116
references: J Cell Physiol. 2003 May;195(2):234-40
references: 12652650
references: Cancer Res. 1987 Jun 15;47(12):3239-45
references: 2438036
references: Br J Cancer. 2002 Feb 12;86(4):636-44
references: 11870549
references: Neurosci Lett. 2011 Jun 22;497(2):80-4
references: 21540076
references: Int J Cancer. 2004 Apr 20;109(4):507-15
references: 14991571
references: Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W741-8
references: 15980575
references: Oncogene. 2011 May 5;30(18):2108-22
references: 21242969
references: Chin Med J (Engl). 2001 Jan;114(1):35-8
references: 11779432
references: Br J Pharmacol. 2001 Jan;132(2):536-46
references: 11159704
references: Jpn J Pharmacol. 1998 Oct;78(2):113-45
references: 9829617
references: Clin Cancer Res. 2000 May;6(5):2104-19
references: 10815938
references: J Clin Invest. 1992 Jan;89(1):191-6
references: 1309535
references: Biochem Biophys Res Commun. 2007 May 11;356(3):723-6
references: 17382903
references: J Cell Physiol. 1983 Mar;114(3):279-83
references: 6833403
references: PLoS One. 2011;6(8):e23464
references: 21850275
references: Mod Pathol. 2005 Apr;18(4):511-8
references: 15475928
references: Adv Pharmacol. 2011;61:373-415
references: 21586365
references: J Biol Chem. 2010 Nov 12;285(46):35462-70
references: 20826776
references: Oncogene. 2013 Oct 10;32(41):4873-82
references: 23160379
references: Cytokine. 2009 May;46(2):166-70
references: 19303321
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: Auton Autacoid Pharmacol. 2007 Apr;27(2):79-84
references: 17391276
references: Purinergic Signal. 2011 Jun;7(2):231-41
references: 21484085
references: Cancer Res. 2006 Sep 1;66(17):8319-26
references: 16951136
references: Cancer Lett. 2010 Jul 28;293(2):189-97
references: 20202742
references: Curr Med Chem Anticancer Agents. 2001 May;1(1):47-70
references: 12678770